Qlucore (QCORE) Q3 2025 earnings summary

Executive summary

• Qlucore Diagnostics BCP-ALL 1.0 received CE marking and IVDR approval, enabling immediate market launch and sales activities post-period.

• Qlucore Omics Explorer 3.10 launched with new statistical methods, but sales impact was below expectations.

• Cost-saving measures, including staff reductions, are underway and expected to yield SEK 4,500k in annual savings.

• Liquidity remains a critical concern; operations can only continue until summer without a significant capital injection.

Financial highlights

• Q3 net sales: SEK 3,217k, down 33% year-over-year; nine-month net sales: SEK 6,747k, down 40%.

• Q3 EBIT: SEK -5,091k (margin -84.6%); nine-month EBIT: SEK -18,718k (margin -146.7%).

• Q3 net result: SEK -5,118k; nine-month net result: SEK -18,597k.

• Cash flow from operating activities Q3: SEK -5,542k; net cash flow Q3: SEK -7,232k.

• Cash and cash equivalents at period end: SEK 11,702k (down from SEK 34,938k year-over-year).

Outlook and guidance

• No formal earnings or market outlook provided; management expects cost savings to take full effect next quarter.

• Liquidity expected to last until summer; urgent capital injection required for continued operations.